Therefore, AGBL5 and/or hyperglutamylation could be explored as targets for therapy in patients with defects in this gene, or other forms of retinal degeneration that involve changes in basal body or ciliary glutamylation levels. This evidence concerns the gene AGBL5 and retinal degeneration.